KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children.

The Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children represents a focused update of Chapter 4: Nephrotic Syndrome in Children from the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. The aim is to assist clinicians caring for individuals with nephrotic syndrome, both steroid sensitive and steroid resistant. The update takes into consideration evidence from randomized controlled trials published through August 2024. As in 2021, this guideline provides guidance related to diagnosis, prognosis, treatment, and special situations. Based on the new evidence, the primary changes in this update are related to the treatment of nephrotic syndrome. Development of this guideline followed an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the certainty of the evidence and the strength of recommendations following the “ Grading of Recommendations Assessment, Development and Evaluation ” (GRADE) approach. Limitations of the evidence are discussed, and areas of future research are also presented.

• Publication year

  2025

• Venue

  Kidney International

• Publication date

  2025-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.kint.2024.11.007PMID 40254391
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An international, multi-center study evaluated rituximab therapy in childhood steroid-resistant nephrotic syndrome.

  2024cited by this paper
• Anti-slit diaphragm antibodies on kidney biopsy identify pediatric patients with steroid-resistant nephrotic syndrome responsive to second-line immunosuppressants.

  2024cited by this paper
• Autoantibodies Targeting Nephrin in Podocytopathies.

  2024cited by this paper
• A multicenter retrospective study of calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene variants.

  2023cited by this paper
• Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.

  2023cited by this paper
• Childhood nephrotic syndrome.

  2023cited by this paper
• Daily low-dose prednisolone to prevent relapse of steroid-sensitive nephrotic syndrome in children with an upper respiratory tract infection: PREDNOS2 RCT.

  2022cited by this paper
• IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome

  2022cited by this paper
• KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.

  2021cited by this paper
• Evaluation of Daily Low-Dose Prednisolone During Upper Respiratory Tract Infection to Prevent Relapse in Children With Relapsing Steroid-Sensitive Nephrotic Syndrome

  2021cited by this paper
• Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial

  2021cited by this paper
• Short-Duration Prednisolone in Children with Nephrotic Syndrome Relapse: A Noninferiority Randomized Controlled Trial.

  2021cited by this paper
• KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

  2021cited by this paper
• Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome

  2021cited by this paper
• Results of the PROPINE randomized controlled study suggest tapering of prednisone treatment for relapses of steroid sensitive nephrotic syndrome is not necessary in children.

  2020cited by this paper
• IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome

  2020cited by this paper
• ADCK4 Deficiency Destabilizes the Coenzyme Q Complex, Which Is Rescued by 2,4-Dihydroxybenzoic Acid Treatment.

  2020cited by this paper
• Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study

  2020cited by this paper
• Efficacy of body weight vs body surface area-based prednisolone regimen in nephrotic syndrome

  2020cited by this paper
• Corticosteroid therapy for nephrotic syndrome in children.

  2020cited by this paper
• Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.

  2020cited by this paper
• Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation

  2019cited by this paper
• Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome

  2019cited by this paper
• Interventions for idiopathic steroid-resistant nephrotic syndrome in children.

  2019cited by this paper
• Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.

  2019cited by this paper
• ADCK4 deficiency destabilizes the coenzyme Q complex, which is rescued by 2,4-dihydroxybenzoic acid treatment

  2019cited by this paper
• Equations to estimate prednisone dose using body weight

  2018cited by this paper
• Idiopathic nephrotic syndrome in children.

  2018cited by this paper
• DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.

  2018cited by this paper
• Systematic Review of the Toxicity of Long-Course Oral Corticosteroids in Children

  2017cited by this paper
• Minimal Change Disease.

  2017cited by this paper
• Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome

  2017influential reference
• Impact of processing methods on urinary biomarkers analysis in neonates

  2017cited by this paper
• NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome.

  2017influential reference
• Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.

  2017cited by this paper
• Efficacy and safety of immunosuppressive medications for steroid-resistant nephrotic syndrome in children: a systematic review and network meta-analysis

  2017cited by this paper
• Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.

  2017cited by this paper
• Efficacy of Levamisole as a single agent in maintaining remission in steroid dependant nephrotic syndrome

  2017cited by this paper
• A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome.

  2017cited by this paper
• Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children.

  2017cited by this paper
• Interventions for idiopathic steroid-resistant nephrotic syndrome in children.

  2016influential reference
• Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial

  2016cited by this paper
• Corticosteroid therapy for nephrotic syndrome in children.

  2015cited by this paper
• Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial

  2015cited by this paper
• Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.

  2015influential reference
• Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome.

  2015cited by this paper
• Non‐Corticosteroid Immunosuppressive Medications for Steroid‐Sensitive Nephrotic Syndrome in Children

  2015influential reference
• A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment

  2014cited by this paper
• Long versus standard initial prednisolone therapy in children with idiopathic nephrotic syndrome.

  2014cited by this paper
• Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.

  2014cited by this paper
• Laboratory Investigation of the Child with Suspected Renal Disease

  2014cited by this paper
• Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.

  2014influential reference
• Long-term outcomes in idiopathic nephrotic syndrome: from childhood to adulthood.

  2014cited by this paper
• Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome.

  2013cited by this paper
• Prevention of steroid-induced low bone mineral density in children with renal diseases: a systematic review.

  2013cited by this paper
• Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome.

  2013cited by this paper
• Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.

  2013cited by this paper
• Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome.

  2012influential reference
• Rituximab in children with resistant idiopathic nephrotic syndrome.

  2012cited by this paper
• The impact of pediatric nephrotic syndrome on families

  2011cited by this paper
• Cyclophosphamide in steroid-dependent nephrotic syndrome

  2011cited by this paper
• Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.

  2011influential reference
• COMMITTEE ON STANDARDS FOR DEVELOPING TRUSTWORTHY CLINICAL PRACTICE GUIDELINES

  2011cited by this paper
• Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome

  2011cited by this paper
• Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial.

  2011cited by this paper
• Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.

  2011cited by this paper
• The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

  2011cited by this paper
• GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology.

  2011cited by this paper
• GRADE guidelines 6. Rating the quality of evidence--imprecision.

  2011cited by this paper
• Clinical trial of focal segmental glomerulosclerosis in children and young adults.

  2011cited by this paper
• Behavioural abnormalities in children with nephrotic syndrome.

  2010cited by this paper
• Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence.

  2010cited by this paper
• AGREE II: advancing guideline development, reporting and evaluation in health care.

  2010cited by this paper
• Successful treatment of steroid-resistant nephrotic syndrome associated with WT1 mutations

  2010cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions

  2010cited by this paper
• Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.

  2009cited by this paper
• Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children.

  2009cited by this paper
• Prednisone dosing per body weight or body surface area in children with nephrotic syndrome—is it equivalent?

  2009cited by this paper
• Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome—a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie

  2008cited by this paper
• Table S5

  2008cited by this paper
• COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement.

  2007cited by this paper
• Table S6

  2007cited by this paper
• Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial

  2007cited by this paper
• Experience with levamisole in frequently relapsing, steroid-dependent nephrotic syndrome

  2006cited by this paper
• Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible

  2006cited by this paper
• Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial.

  2006cited by this paper
• Long-term results of two unconventional agents in steroid-dependent nephrotic children

  2005cited by this paper
• Longitudinal follow-up of bone mineral density in children with nephrotic syndrome and the role of calcium and vitamin D supplements.

  2005cited by this paper
• Steroid-sensitive nephrotic syndrome: from childhood to adulthood.

  2003cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Increased Maintenance Corticosteroids during Upper Respiratory Infection Decrease the Risk of Relapse in Nephrotic Syndrome

  2000cited by this paper
• Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome

  1999cited by this paper
• A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.

  1999cited by this paper
• Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children.

  1997cited by this paper
• Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome

  1997cited by this paper
• Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults.

  1997cited by this paper
• [Initial therapy of primary nephrotic syndrome in children: evaluation in a period of 18 months of two prednisone treatment schedules. Chilean Co-operative Group of Study of Nephrotic Syndrome in Children].

  1996cited by this paper
• Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis

  1996cited by this paper
• Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children

  1996cited by this paper
• A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children.

  1996cited by this paper

• B-Cell Depletion in Glomerular Diseases: Not Always as Safe as We May Think

  2026cites this paper
• Neuraminidase activity in pediatric nephrotic syndrome.

  2026cites this paper
• Proteinuria in adolescence.

  2026cites this paper
• The safety of rituximab in pediatric nephrotic syndrome patients: a pharmacovigilance study of the FAERS database.

  2026cites this paper
• KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children.

  2026cites this paper
• A Case of Pulmonary Thromboembolism in a Child With Steroid-Resistant Nephrotic Syndrome.

  2026cites this paper
• A Retrospective Cohort Analysis of Short-Term Outcomes of the Mycophenolate Mofetil-Based Triple Regimen for the Treatment of Calcineurin Inhibitor-Resistant Childhood Nephrotic Syndrome: A Single-Center Experience.

  2026cites this paper
• Polygenic risk score from steroid-sensitive nephrotic syndrome GWAS indicates overlapping genetic basis with steroid-resistant cases

  2026cites this paper
• Single relapse at ≥ 0.5 mg/kg alternate-day prednisone predicts course of childhood nephrotic syndrome.

  2026cites this paper
• Nomogram‐Based Admission Model to Predict Early Hypovolaemic Shock in Paediatric Nephrotic Syndrome: Derivation and Internal Validation

  2026cites this paper
• Low-density lipoprotein apheresis for recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: a systematic review and meta-analysis.

  2026cites this paper
• Ciclosporin-Induced Generalised Hypertrichosis in a Transgender Woman Receiving Testosterone Blockers

  2026cites this paper
• Treatment outcomes and ongoing pediatric trials in steroid-resistant nephrotic syndrome.

  2026cites this paper
• Infection prophylaxis following anti-CD20 monoclonal antibodies in childhood kidney diseases.

  2026cites this paper
• Successful Therapy with Obinutuzumab in a Toddler with Primary Multidrug-Resistant Nephrotic Syndrome

  2025cites this paper
• Podocytopathies

  2025cites this paper
• The 2025 KDIGO guideline on the management of nephrotic syndrome in children: a comment of the European Renal Association Immunonephrology Working Group

  2025cites this paper
• Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: Biological challenges and clinical implications.

  2025cites this paper
• Steroid-Dependent Nephrotic Syndrome With Remission After Rituximab Implementation in a 14-Year-Old Boy: A Case Report

  2025cites this paper
• CARI Guidelines Commentary on the KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases

  2025cites this paper
• KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

  2025cites this paper
• Optimizing mycophenolic acid exposure for reduced relapse risk in paediatric nephrotic syndrome: An observational cohort study

  2025cites this paper
• Clinical characteristics of children with idiopathic nephrotic syndrome infected with SARS-CoV-2: a single-center retrospective cohort study

  2025influential citation
• Challenging Clinical Practice Guideline Definitions in Childhood Nephrotic Syndrome.

  2025cites this paper
• Whole-Exome Sequencing for Molecular Diagnosis of Paediatric Nephrotic Syndrome in Africa: A Call for Implementation

  2025cites this paper
• TREATMENT OF MINIMAL CHANGE DISEASE IN ADULTS: CURRENT PRACTICE AND FUTURE DIRECTIONS – A NARRATIVE LITERATURE REVIEW

  2025cites this paper
• Prevalence of histopathological subtypes associated with steroid-resistant nephrotic syndrome in children: a systematic review and meta-analysis

  2025cites this paper
• Equity in evidence: Overcoming barriers to kidney trials in low-resource settings.

  2025cites this paper
• Professor Emeritus Visith Sitprija, MD, Ph.D. Endowed Lectureship: Kidney Diseases Across a Lifespan

  2025cites this paper
• Optimal selection and timing of steroid-sparing therapy in childhood nephrotic syndrome: what determines long-term outcomes of adult survivors?

  2025cites this paper